Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study - 14/01/19
This study is subject to Stanford Human Subjects Approval Protocol 34925 and is listed at clinicaltrials.gov (NCT02690948). |
|
Merck, Sharp, and Dohme, Inc. provided funding for this study but were not involved in writing of the manuscript, decision to submit for publication, data collection, analysis, interpretation, trial design, patient recruitment or any other aspect pertinent to the study. The authors have not been paid to write this article by a pharmaceutical company or other agency. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication. |
|
Dr Chang was a consultant for Merck, Sharp and Dohme, Inc, is a clinical investigator for studies sponsored by Regeneron, Genentech-Roche, and Novartis. Ms Yost is funded by grants from the National Science Foundation, National Institutes of Health, and Parker Institute for Cancer Immunotherapy. The other authors have no conflicts of interest to disclose. |
Vol 80 - N° 2
P. 564-566 - février 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?